Loading
A phase 1/2 trial of CT7439 Capsules (0.5 mg, 1mg, 3mg, 10mg, 15mg, 20mg) in advanced solid tumours, run by Carrick Therapeutics Limited, now recruiting.
A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies is a phase 1/2 interventional study registered as NCT06600789 by Carrick Therapeutics Limited, with 50 participants planned, started 2024-08-16 and due to reach its primary completion in 2027-03-14. Interventions recorded: CT7439 Capsules (0.5 mg, 1mg, 3mg, 10mg, 15mg, 20mg).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/